Discover the current definitions, classifications, treatment options and prognosis for myelodysplastic/myeloproliferative neoplasms.
Browsing: Disease Area > Hematologic
Researchers have demonstrated that transcription factor RUNX1, which has known tumor-suppressor function, may induce acute myeloid leukemia in cooperation with FLT3.
In this review article from the International Journal of Hematologic Oncology read about the clinical benefits of utilizing tyrosine kinase inhibitors in combination with chemotherapy regimes for Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
This opinion article from Immunotherapy looks at how antigen-directed therapies could hold potential for the treatment of acute myeloid leukemia and the challenges of their use to date.
Researchers have discovered that overexpression of the protein TRAF6 is a driver of myelodysplasia syndromes and have used this to identify possible new molecular targets.
Could targeting IDH mutations in acute myeloid leukemia reprogram the epigenome for therapeutic gain? Read more in the review from Epigenomics.
Researchers have developed a personalized vaccine for acute myeloid leukemia patients in remission, which may be protective against disease relapse.
Early-phase trial demonstrates that CD19-targeted CAR T-cell infusions reduced disease levels in chronic lymphocytic leukemia.
Researchers have demonstrated that acute myeloid leukemia patients who carry TP53 mutations respond better to a milder form of chemotherapy.
In this review the authors discuss the potential of noncoding RNAs as novel therapeutic targets and biomarkers in acute myeloid leukemia.